SrasV1, Main, Curation, bibRecord, 001786

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Identifieur interne : 001786 ( Main/Curation ); précédent : 001785; suivant : 001787

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Auteurs : Christopher M. Coleman [États-Unis] ; Ye V. Liu [États-Unis] ; HAIYAN MU [États-Unis] ; Justin K. Taylor [États-Unis] ; Michael Massare [États-Unis] ; David C. Flyer [États-Unis] ; Gregory M. Glenn [États-Unis] ; Gale E. Smith [États-Unis] ; Matthew B. Frieman [États-Unis]

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0134129

Descripteurs français

KwdFr :
- Adjuvants immunologiques (administration et posologie), Animaux, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Coronavirus, Glycoprotéine de spicule des coronavirus (biosynthèse), Glycoprotéine de spicule des coronavirus (immunologie), Infections à coronavirus (), Nanoparticules, Protection croisée, Protéines recombinantes (biosynthèse), Protéines recombinantes (immunologie), Souris, Souris de lignée BALB C, Tests de neutralisation, Vaccins antiviraux (immunologie).
MESH :
- administration et posologie : Adjuvants immunologiques.
- biosynthèse : Glycoprotéine de spicule des coronavirus, Protéines recombinantes.
- immunologie : Glycoprotéine de spicule des coronavirus, Protéines recombinantes, Vaccins antiviraux.
- sang : Anticorps antiviraux, Anticorps neutralisants.
Pascal (Inist)
- Animaux, Coronavirus, Infections à coronavirus, Nanoparticules, Protection croisée, Souris, Protéine, Nanoparticule, Anticorps neutralisant, Moyen Orient, Souris de lignée BALB C, Tests de neutralisation, Vaccin, Syndrome respiratoire aigu sévère.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Coronavirus, Coronavirus Infections (prevention & control), Cross Protection, Mice, Mice, Inbred BALB C, Middle east, Mouse, Nanoparticle, Nanoparticles, Neutralization Tests, Neutralizing antibody, Protein, Recombinant Proteins (biosynthesis), Recombinant Proteins (immunology), Severe acute respiratory syndrome, Spike Glycoprotein, Coronavirus (biosynthesis), Spike Glycoprotein, Coronavirus (immunology), Vaccine, Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic.
- chemical , biosynthesis : Recombinant Proteins, Spike Glycoprotein, Coronavirus.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Recombinant Proteins, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- prevention & control : Coronavirus Infections.
- Animals, Coronavirus, Cross Protection, Mice, Mice, Inbred BALB C, Nanoparticles, Neutralization Tests.

Abstract

Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058772

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000006
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000981
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000005
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001792
to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001537
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :001537
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000862
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001007
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001007
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F45
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002874
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002874
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002874
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001594

Links to Exploration step

Pascal:14-0134129

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0134129</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0134129 INIST</idno>
<idno type="RBID">Pascal:14-0134129</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000006</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000981</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000005</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000005</idno>
<idno type="wicri:doubleKey">0264-410X:2014:Coleman C:purified:coronavirus:spike</idno>
<idno type="wicri:Area/Main/Merge">001792</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058772</idno>
<idno type="RBID">PMC:4058772</idno>
<idno type="wicri:Area/Pmc/Corpus">001537</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001537</idno>
<idno type="wicri:Area/Pmc/Curation">001537</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001537</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000862</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000862</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:24736006</idno>
<idno type="wicri:Area/PubMed/Corpus">001007</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001007</idno>
<idno type="wicri:Area/PubMed/Curation">001007</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001007</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F45</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F45</idno>
<idno type="wicri:Area/Ncbi/Merge">002874</idno>
<idno type="wicri:Area/Ncbi/Curation">002874</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002874</idno>
<idno type="wicri:doubleKey">0264-410X:2014:Coleman C:purified:coronavirus:spike</idno>
<idno type="wicri:Area/Main/Merge">001594</idno>
<idno type="wicri:Area/Main/Curation">001786</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Coronavirus</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Cross Protection</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Middle east</term>
<term>Mouse</term>
<term>Nanoparticle</term>
<term>Nanoparticles</term>
<term>Neutralization Tests</term>
<term>Neutralizing antibody</term>
<term>Protein</term>
<term>Recombinant Proteins (biosynthesis)</term>
<term>Recombinant Proteins (immunology)</term>
<term>Severe acute respiratory syndrome</term>
<term>Spike Glycoprotein, Coronavirus (biosynthesis)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Vaccine</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Coronavirus</term>
<term>Glycoprotéine de spicule des coronavirus (biosynthèse)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Infections à coronavirus ()</term>
<term>Nanoparticules</term>
<term>Protection croisée</term>
<term>Protéines recombinantes (biosynthèse)</term>
<term>Protéines recombinantes (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Tests de neutralisation</term>
<term>Vaccins antiviraux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Recombinant Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Recombinant Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines recombinantes</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Coronavirus</term>
<term>Cross Protection</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nanoparticles</term>
<term>Neutralization Tests</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus</term>
<term>Infections à coronavirus</term>
<term>Nanoparticules</term>
<term>Protection croisée</term>
<term>Souris</term>
<term>Protéine</term>
<term>Nanoparticule</term>
<term>Anticorps neutralisant</term>
<term>Moyen Orient</term>
<term>Souris de lignée BALB C</term>
<term>Tests de neutralisation</term>
<term>Vaccin</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.</div>
</front>
</TEI>
<double idat="0264-410X:2014:Coleman C:purified:coronavirus:spike"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0134129</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0134129 INIST</idno>
<idno type="RBID">Pascal:14-0134129</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000006</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000981</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000005</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000005</idno>
<idno type="wicri:doubleKey">0264-410X:2014:Coleman C:purified:coronavirus:spike</idno>
<idno type="wicri:Area/Main/Merge">001792</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1>
<s2>Gaithersburg, MD 20852</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1>
<s2>Baltimore, MD 21201</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Middle east</term>
<term>Mouse</term>
<term>Nanoparticle</term>
<term>Neutralizing antibody</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Souris</term>
<term>Protéine</term>
<term>Nanoparticule</term>
<term>Anticorps neutralisant</term>
<term>Moyen Orient</term>
<term>Vaccin</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.</div>
</front>
</TEI>
</INIST>
<PMC><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mu, Haiyan" sort="Mu, Haiyan" uniqKey="Mu H" first="Haiyan" last="Mu">Haiyan Mu</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name>
<affiliation wicri:level="4"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24736006</idno>
<idno type="pmc">4058772</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058772</idno>
<idno type="RBID">PMC:4058772</idno>
<idno type="doi">10.1016/j.vaccine.2014.04.016</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">001537</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001537</idno>
<idno type="wicri:Area/Pmc/Curation">001537</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001537</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000862</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000862</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:24736006</idno>
<idno type="wicri:Area/PubMed/Corpus">001007</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001007</idno>
<idno type="wicri:Area/PubMed/Curation">001007</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001007</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F45</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F45</idno>
<idno type="wicri:Area/Ncbi/Merge">002874</idno>
<idno type="wicri:Area/Ncbi/Curation">002874</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002874</idno>
<idno type="wicri:doubleKey">0264-410X:2014:Coleman C:purified:coronavirus:spike</idno>
<idno type="wicri:Area/Main/Merge">001594</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mu, Haiyan" sort="Mu, Haiyan" uniqKey="Mu H" first="Haiyan" last="Mu">Haiyan Mu</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name>
<affiliation wicri:level="4"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Coronavirus</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Cross Protection</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nanoparticles</term>
<term>Neutralization Tests</term>
<term>Recombinant Proteins (biosynthesis)</term>
<term>Recombinant Proteins (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (biosynthesis)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Coronavirus</term>
<term>Glycoprotéine de spicule des coronavirus (biosynthèse)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Infections à coronavirus ()</term>
<term>Nanoparticules</term>
<term>Protection croisée</term>
<term>Protéines recombinantes (biosynthèse)</term>
<term>Protéines recombinantes (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Tests de neutralisation</term>
<term>Vaccins antiviraux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Recombinant Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Recombinant Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines recombinantes</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Coronavirus</term>
<term>Cross Protection</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nanoparticles</term>
<term>Neutralization Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus</term>
<term>Infections à coronavirus</term>
<term>Nanoparticules</term>
<term>Protection croisée</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Highlights</title>
<p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>•</label>
<p id="par0005">Emergence of MERS-CoV demonstrates the need for novel vaccine strategies against coronaviruses.</p>
</list-item>
<list-item id="lsti0010"><label>•</label>
<p id="par0010">Production of novel nanoparticle vaccine containing full spike protein of MERS-CoV and SARS-CoV.</p>
</list-item>
<list-item id="lsti0015"><label>•</label>
<p id="par0015">Higher titer neutralizing antibody produced in vaccinated mice.</p>
</list-item>
<list-item id="lsti0020"><label>•</label>
<p id="par0020">Vaccination in combination with a new adjuvant, Matrix M1, boosts neutralizing antibody titer.</p>
</list-item>
</list>
</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Jackwood, M W" uniqKey="Jackwood M">M.W. Jackwood</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Song, D" uniqKey="Song D">D. Song</name>
</author>
<author><name sortKey="Park, B" uniqKey="Park B">B. Park</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Ding, Y" uniqKey="Ding Y">Y. Ding</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Kuiken, T" uniqKey="Kuiken T">T. Kuiken</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lau, S K" uniqKey="Lau S">S.K. Lau</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Poon, L L" uniqKey="Poon L">L.L. Poon</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Ge, X Y" uniqKey="Ge X">X.Y. Ge</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Mailles, A" uniqKey="Mailles A">A. Mailles</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Masters, P S" uniqKey="Masters P">P.S. Masters</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Belouzard, S" uniqKey="Belouzard S">S. Belouzard</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Qiu, M" uniqKey="Qiu M">M. Qiu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Zhu, X" uniqKey="Zhu X">X. Zhu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Tseng, C T Et Al" uniqKey="Tseng C">C.T.et al. Tseng</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Spruth, M" uniqKey="Spruth M">M. Spruth</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Qin, E" uniqKey="Qin E">E. Qin</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lin, J T" uniqKey="Lin J">J.T. Lin</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Bolles, M" uniqKey="Bolles M">M. Bolles</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Li, J" uniqKey="Li J">J. Li</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="He, Y" uniqKey="He Y">Y. He</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Shim, B S" uniqKey="Shim B">B.S. Shim</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Bisht, H" uniqKey="Bisht H">H. Bisht</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Feng, Q" uniqKey="Feng Q">Q. Feng</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Yang, Z Y" uniqKey="Yang Z">Z.Y. Yang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Martin, J E" uniqKey="Martin J">J.E. Martin</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lu, B" uniqKey="Lu B">B. Lu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Liu, Y V" uniqKey="Liu Y">Y.V. Liu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lu, X" uniqKey="Lu X">X. Lu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Bai, B Et Al" uniqKey="Bai B">B.et al. Bai</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lokugamage, K G" uniqKey="Lokugamage K">K.G. Lokugamage</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lu, B" uniqKey="Lu B">B. Lu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Almazan, F" uniqKey="Almazan F">F. Almazan</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Song, F" uniqKey="Song F">F. Song</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="De Groot, A S" uniqKey="De Groot A">A.S. De Groot</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Reed, L J" uniqKey="Reed L">L.J. Reed</name>
</author>
<author><name sortKey="Muench, H" uniqKey="Muench H">H. Muench</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Simons, K" uniqKey="Simons K">K. Simons</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Smith, G" uniqKey="Smith G">G. Smith</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Glenn, G M" uniqKey="Glenn G">G.M. Glenn</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lovgren Bengtsson, K" uniqKey="Lovgren Bengtsson K">K. Lovgren Bengtsson</name>
</author>
<author><name sortKey="Morein, B" uniqKey="Morein B">B. Morein</name>
</author>
<author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Cox, R J" uniqKey="Cox R">R.J. Cox</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Devitt, E" uniqKey="Devitt E">E. Devitt</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Coleman, C M" uniqKey="Coleman C">C.M. Coleman</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</PMC>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001786 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001786 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0134129
   |texte=   Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri